Plain-English translation of NCT06052254 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing dexmedetomidine transdermal systems (DMTS)—a new medication delivered through a skin patch—to see if it can help calm agitation in people with Alzheimer's disease. Participants will wear patches on their upper back for 4 days at a time, with a second treatment round two weeks later. The study will compare different patch doses against placebo (inactive) patches to find out what works best.
People with Alzheimer's disease often experience episodes of agitation that can be distressing and difficult to manage with current treatments. This medication is being tested to see if delivering it through the skin could offer a gentler, safer way to reduce these episodes.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to receive either two active patches, one active and one inactive patch, or two inactive patches—all applied to your upper back. You'll wear the patches for 4 days straight, then have a 2-week break, and then wear the same patches for another 4 days if you're eligible for the second round. During this time, staff will monitor you for any changes in your agitation and overall well-being.
AI-generated summary from trial data · Jul 5, 2026 · Not medical advice
United States